For research use only. Not for therapeutic Use.
Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor[1][2].
Terevalefim (ANG-3777) (0-10 μM) significantly inhibited cancer cells proliferation in HUVECs[2].
Terevalefim (ANG-3777) decreases apoptosis, increases proliferation, and promotes organ repair and function in animal models[1].
Terevalefim (ANG-3777, 40 mg/kg, IP) phosphorylates the c-Met receptor in rats[2].
| Catalog Number | I044671 |
| CAS Number | 1070881-42-3 |
| Synonyms | 5-[(E)-2-thiophen-2-ylethenyl]-1H-pyrazole |
| Molecular Formula | C9H8N2S |
| Purity | ≥95% |
| InChI | InChI=1S/C9H8N2S/c1-2-9(12-7-1)4-3-8-5-6-10-11-8/h1-7H,(H,10,11)/b4-3+ |
| InChIKey | FOHWAQGURRYJFK-ONEGZZNKSA-N |
| SMILES | C1=CSC(=C1)C=CC2=CC=NN2 |
| Reference | [1]. Jonathan S Bromberg, et al. Renal Function Improvement Following ANG-3777 Treatment in Patients at High Risk for Delayed Graft Function After Kidney Transplantation. Transplantation. 2021 Feb 1;105(2):443-450. [2]. Latha Paka, et al. The Effect of ANG-3777 on Hepatocyte Growth Factor Receptor, c-MET Signaling. American Transplant Society. |
